Precision Health Track Banner

Cambridge Healthtech Institute’s Inaugural

Precision Health

Prediction, Prevention, and Early Detection for Health and Wellness

February 21-22, 2022

 

As the next step after precision medicine, we need to shift from “sick-care” to “healthcare.” Cambridge Healthtech Institute’s Inaugural Precision Health meeting convenes the main stakeholders in advancing precision health, focusing on prediction, prevention, and early detection for individualized health and wellness. Technology innovations driving precision health include community-wide genetic screening and early disease detection, preventative health strategies, AI and digital health tools, at-home diagnostics and monitoring, personalized lifestyle and wellness. Investment, regulatory, and market access strategies for the emerging precision health technologies will be discussed.

Monday, February 21

7:00 am Registration Open and Morning Coffee (Indigo West Foyer AB)

ROOM LOCATION: Indigo 202 A

GENOMICS AND MOLECULAR PHENOTYPING FOR PRECISION HEALTH

7:55 am

Chairperson's Remarks

Erica F. Sanford Kobayashi, MD, Assistant Professor, Rady Children's Hospital, San Diego
8:00 am

Precision Health Equity

Megan Mahoney, MD, Clinical Professor, Primary Care & Population Health, Stanford University

There is an unprecedented opportunity for healthcare to harness the power of new streams of patient monitoring and genetic data to tailor chronic disease management and cancer prevention for the unique patient in front of us. When we implemented Humanwide, a primary care project that used mobile monitoring devices regularly to track blood pressure, activity and weight, data was synthesized by the healthcare team to develop a care plan based on the patient’s goals with the principle of health equity in mind. Precision health can be more effective, more responsive, and treats the whole person.

8:30 am

Ultra-Rapid Whole Genome Sequencing in Critically Ill Children: Where We’re at, Where We’re Going, and How We Get There

Erica F. Sanford Kobayashi, MD, Assistant Professor, Rady Children's Hospital, San Diego

There are currently more than 6,700 known single-locus disorders. Using phenotype-driven ultra-rapid whole genome sequencing (urWGS), it is possible to diagnose genetic disorders in as little as 13.5 hours, facilitating changes in clinical management from empiric therapy to disease-specific treatment and improving patient outcomes. urWGS diagnostic and clinical utility are well-established in neonatal and pediatric intensive care units, and next steps include scalability and widespread dissemination, areas in which automation (such as artificial intelligence and natural language processing) will play a significant role.

9:00 am

Population Genetic Screening: The Impact of the Sanford Chip Program

Kurt D. Christensen, PhD, Assistant Professor, Population Medicine, Harvard Pilgrim Health Care Institute

In 2018, Sanford Health began offering its primary care patients the Sanford Chip, a genetic test that provides pharmacogenomic profiling and optional screening for medically actionable predispositions. This talk summarizes data about the impact of the Sanford Chip program on healthcare providers and patients. Findings that will be discussed include the effectiveness of mandatory provider education efforts, the frequency of informative genetic findings, and early results about patient outcomes.

9:30 am Session Break

INTERACTIVE DISCUSSIONS

9:45 am Interactive Discussions (In-person only)

Interactive Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. For in-person events, the facilitator will lead from the front of the room while attendees remain seated to promote social distancing.  To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. Please visit the Interactive Discussion page on the conference website for a complete listing of topics and descriptions.

GENOMICS AND MOLECULAR PHENOTYPING FOR PRECISION HEALTH (CONT.)

10:15 am

Scientific Wellness and Deep Phenotyping to Enhance Human Health

Nathan D. Price, PhD, CSO, Thorne HealthTech

An increasing focus on wellness and prevention is key to dealing with chronic diseases that drive most health costs today.  Enabling predictive and preventive approaches requires the generation of dense data on healthy people to quantify wellness states and to observe the earliest transitions to disease. I will discuss how such 'deep phenotyping’ data is used to drive biological discovery and improve health.

10:45 am

High-Tech, High-Touch – Accelerating Population-Scale Genomics with Technology and Comprehensive Genomic Services

Erica Ramos, Vice President, Population Genomics, Genome Medical

Genomic medicine promises to help people understand and manage their health with individualized and actionable insights. An increasing number of health systems, biopharma companies, and others seek to build the programs needed to deliver on this promise, whether centered in research, clinical care or both. True end-to-end development, technology-enabled solutions, and scalable genetic services are required to deliver the right care to the right patient at the right time.

11:15 am

A Gene Expression Discovery Platform for Large-Scale Studies of Chronic Diseases

Guru Banavar, PhD, CTO & Head of Discovery AI, Viome Life Sciences

The interaction between the microbiome and the human host holds the key to the triggers and progression of many chronic diseases. By analyzing large host-microbiome gene expression datasets obtained from blood, stool, and saliva samples, we have discovered biomarkers and therapeutic targets for multiple chronic diseases and cancer, and translated them into clinical applications. We invite collaborators to leverage our platform to discover insights at this frontier of systems biology.

11:45 am Enjoy Lunch on Your Own
1:20 pm Session Break

INNOVATION AND GROWTH OPPORTUNITIES IN PRECISION HEALTH

1:30 pm

Chairperson's Remarks

Taha Jangda, Partner, HealthX Ventures
1:35 pm

Precision Medicine Minefields - An Investor’s Perspective

Adam Dakin, Partner, HealthTech, Dreamit Ventures

Fresh off a record year of venture dollars into health technology, investment interest in precision medicine and digital health is quickly picking up speed. But venture dollars and market adoption don't always see eye-to-eye. In this interactive discussion, Adam Dakin, Partner of Dreamit Venture's healthtech investment vertical, highlights the adoption barriers that precision medicine companies currently face and what the sector needs to overcome to meet the promise (and returns) that investors expect.


2:05 pm

2022 Healthcare Investments and Exits Report

Milo Bissin, Director, Life Sciences and Healthcare, Silicon Valley Bank

What’s driving innovation in healthcare? SVB provides unique insight into the ecosystem with its industry-leading reports featuring proprietary analysis and targeted outlooks informed by our deep relationships with top healthcare entrepreneurs and investors. Twice a year we publish deep-dive analysis of fundraising, investment and exit activity of private, venture-backed biopharma, healthtech, diagnostics/tools and device companies to help companies and investors achieve their goals.

2:35 pm

Precision Medicine: New Categories and Implementation

Taha Jangda, Partner, HealthX Ventures

For the adoption of technologies to become tangible and real, we need to continue to evaluate them with great scientific vigor. Join the conversation to take a deep dive into the promise of precision medicine and how it can be best used in practice.

Brian Leyland-Jones, MBBS, PhD, Dr., Parthen

Parthen offers precision oncology services to patients, their caregivers, and Primary Clinical Care Team.  Using a patient-centered globally connected digital health platform, Parthen offers guidance on molecular testing, patient advocacy/navigation services and medication acquisition specialists to best support cancer patients and their families. 

3:35 pm Session Break

KEYNOTE LOCATION: Indigo A

PLENARY KEYNOTE SESSION: PRECISION HEALTH: GENOMICS AND BEYOND

4:15 pm

Chairperson's Remarks

Robert C. Green, MD, MPH, Professor and Director of Genomes2People Research, Mass General Brigham, Broad Institute, Ariadne Labs and Harvard Medical School
Stephen Williams, MD, PhD, CMO, SomaLogic

Reliable outcomes prediction enables increased power in clinical trials and improved allocation of resources in clinical practice. The new discipline of using highly multiplexed measurements, machine learning and mixed study populations can lead to robust and generalized predictors of catastrophic and near-term risks. Key examples using SomaScan® proteomics for cardiovascular events, heart failure mortality and loss of kidney function will be shown.

4:30 pm

Universal Newborn Sequencing and the Path to Preventive Genomics

Robert C. Green, MD, MPH, Professor and Director of Genomes2People Research, Mass General Brigham, Broad Institute, Ariadne Labs and Harvard Medical School

Twenty years after the completion of the Human Genome Project, there is beginning to be broad acceptance for returning actionable genomic findings as an ethical imperative in large-scale genomic research, as secondary findings in indication-based sequencing, and as population-scale screening in forward-looking healthcare systems. While the evident data on patient-provider acceptability, clinical utility and cost-benefit are far from comprehensive, empirical research from many domains suggest that when unanticipated genomic information is delivered, patients are deeply interested and do not experience unusual distress, providers can manage disclosure and care with appropriate support, and downstream healthcare utilization is modest and appropriate. We recently completed the first randomized trial of comprehensive genome sequencing in healthy newborns and are beginning a multi-site second phase of this research (the NIH funded BabySeq Project). We present data from this and other studies to suggest that universal newborn sequencing may be well-tolerated and cost-effective, and may soon provide a platform for the lifelong use of genomics in risk stratification, disease mitigation and expanding longevity.

5:00 pm

Transforming Genomic Healthcare in the United Kingdom

Sir Mark Caulfield, PhD, Professor & Director, Clinical Pharmacology, The William Harvey Research Institute, Queen Mary University of London; CEO, Barts Life Sciences

The 100,000 Genomes Project focused on rare disease, cancer, and infection and demonstrated the potential of whole genomes to uplift diagnoses by 25% in rare disease, have a clinical utility for 25% of cancer patients, and discover 15 novel gene loci for severe COVID-19. Exploring of pharmacogenomics reveals many of us have genetic variants which if paired with a drug may cause harm. To do this we created a new National Test Directory where we evaluated 300,000 tests upgraded 25% to new technologies, and 500,000 whole genomes are available for rare disease and cancer care over the next 5 years. We have used this to transform the National Health Service with a new Genomic Medicine Service offering equitable access to 56 million people.

5:30 pm

Precision Health: Closing the Information and Decision Gaps

Jessica L. Mega, MD, MPH, Co-Founder and Chief Medical & Scientific Officer, Verily; Adjunct Professor, Stanford University School of Medicine

Genomic insights have proven to be powerful, from providing a better interpretation of the pathobiology of disease to tailoring medications based on pharmacogenetics. At the same time, there has been a growing appreciation that a multitude of inputs are needed to provide a comprehensive understanding of both the health of an individual and how it relates to the broader population. Accounting for (1) the highly complex interplay of biological, behavioral, environmental, and social systems, and (2) the changes in the cadence of data collection from episodic to continuous will be critical to improving clinical outcomes. The scale of data, from gigabytes to terabytes per individual, necessitates an updated framework to collect, organize, and activate this rich health information; recent advances in biomedical information systems and computation are making these activities possible. Additionally, tools to harness more comprehensive biological insights are being developed, and people are interacting more directly with their health data, along with the support of researchers and clinicians. All these efforts to close the information and decision gaps will ultimately advance precision health.

6:00 pm PANEL DISCUSSION:

Precision Health: Convergence of Genomics, Digital MedTech and Healthcare

Panel Moderator:
Robert C. Green, MD, MPH, Professor and Director of Genomes2People Research, Mass General Brigham, Broad Institute, Ariadne Labs and Harvard Medical School

Precision Health promises a much-needed shift from “sick-care” to “healthcare.” Driven by innovations in genomics, medtech, and AI, precision health strategies can focus on prediction, prevention, and early detection for individualized health and wellness. The panel will discuss how genomics and digital health technologies can advance community-wide genetic screening and early disease detection, patient monitoring and preventative health strategies, personalized lifestyle and wellness approaches, and precision health equity.

Panelists:
Sir Mark Caulfield, PhD, Professor & Director, Clinical Pharmacology, The William Harvey Research Institute, Queen Mary University of London; CEO, Barts Life Sciences
Jessica L. Mega, MD, MPH, Co-Founder and Chief Medical & Scientific Officer, Verily; Adjunct Professor, Stanford University School of Medicine
Lara Jehi, MD, Chief Research Information Officer, Professor, Neurology, Cleveland Clinic
Megan Mahoney, MD, Clinical Professor, Primary Care & Population Health, Stanford University
6:30 pm Welcome Reception in the Exhibit Hall with Poster Viewing
7:30 pm Close of Day

Tuesday, February 22

7:30 am Registration Open and Morning Coffee

ROOM LOCATION: Indigo 202 A

BIG DATA, AI AND DIGITAL MEDICINE AS DRIVERS OF PRECISION HEALTH

7:55 am

Chairperson's Remarks

Jay Pandit, MD, Director, Digital Medicine, Scripps Research Translational Institute; Adjunct Professor, Scripps Research; Assistant Professor, Division of Cardiology, Northwestern University Feinberg School of Medicine
8:00 am

Big Data, Health, and COVID-19

Michael Snyder, PhD, Stanford W. Ascherman Professor & Chair, Department of Genetics; Director, Center for Genomics & Personalized Medicine, Stanford University

Recent technological advances as well as longitudinal monitoring not only have the potential to improve the treatment of disease (Precision Medicine) but also empower people to stay healthy (Precision Health). We have been using advanced multiomics technologies (genomics, immunomics, transcriptomics, proteomics, metabolomics, microbiomics) as well as wearables for monitoring health in 109 individuals for up to 11 years and made numerous major health discoveries covering cardiovascular disease, oncology, metabolic health and infectious disease. We have found that individuals have distinct aging patterns that can be measured in an actionable period of time as well as seasonal patterns of health markers. Finally, we have used wearable devices for early detection of infectious disease, including COVID-19 and built an alerting system for detecting health stressors that is scaleable to the entire planet. We believe that advanced technologies have the potential to transform healthcare.

8:30 am

Accelerating Precision Medicine at a Health-System Level

Lara Jehi, MD, Chief Research Information Officer, Professor, Neurology, Cleveland Clinic

Accelerating precision medicine at a Health System level is the holy grail for patients and healthcare professionals alike. Several technical, regulatory, and cultural hurdles currently complicate the largescale implementation of data-driven individualized healthcare decisions and precision medicine approaches. This talk will review a vision for “learning from a million patients to better care for the one” through scalable biobanking and research information solutions in the Cleveland Clinic Health System.

Jeanette McCarthy, MPH, PhD, Vice President, Precision Medicine, Fabric Genomics

Diagnostic sequencing for rare disease using whole genome is becoming a routine part of care for critically ill newborns as well as children with undiagnosed diseases, enabled by Fabric Genomics GEM AI technology. This technology is now being leveraged for identifying disease-causing variants among ostensibly healthy individuals in the screening setting. Potential applications, including genome-wide newborn screening, carrier testing and adult hereditary risk profiling, will be discussed.

9:30 am Coffee Break in the Exhibit Hall with Poster Viewing
10:10 am

The Future of Health Data and Precision Medicine

Ardy Arianpour, CEO & Co-Founder, Seqster

High fidelity, high-quality Real World Data can be obtained by placing the patient at the center, breaking down data silos to obtain comprehensive, longitudinal health data. Such data is critical for Precision Medicine as well as for clinical studies leading to the discovery of novel cures. Health Data is Medicine.

10:40 am

Person-Generated Health Data (PGHD): Applications in Research, Healthcare, and Public Health

Luca Foschini, PhD, Co-Founder & Chief Data Scientist, Evidation Health Inc.

Dr. Foschini will give examples of applications of Person-Generated Health Data (PGHD) across therapeutic areas, including post-op monitoring, screening for cognitive impairment, and COVID-19 detection and quantification. Finally, Dr. Foschini will discuss lessons learned in translating PGHD research into benefit for the individuals, and how good analytic performance is a necessary but not at all sufficient condition to engender the trust that clinical investigators, doctors, regulators, and ultimately individuals seek.

11:10 am

Democratizing Digital Trials: The First Step in Personalizing the Practice of Digital Medicine

Jay Pandit, MD, Director, Digital Medicine, Scripps Research Translational Institute; Adjunct Professor, Scripps Research; Assistant Professor, Division of Cardiology, Northwestern University Feinberg School of Medicine

In an era of smart devices and sensors, we now have the ability to finally understand our patient's physiology beyond the snapshots we get in the clinic. However, many clinical studies continues to rely on the bottleneck of referrals through clinic visits. In this talk we will discuss the major digital clinical studies, the promises and challenges of digital clinical trials and some future directions.

11:40 am Session Break
11:50 am Enjoy Lunch on Your Own
12:20 pm Refreshment Break in the Exhibit Hall with Poster Viewing (Indigo BFGCDH)
1:00 pm Close of Precision Health Conference





Register Now
March 11-12, 2025

Artificial Intelligence in Precision Medicine

Implementing Precision Medicine

At-Home & Point-of-Care Diagnostics

Liquid Biopsy

Spatial Biology and Single-Cell Multiomics

March 12-13, 2025

Diagnostics Market Access

Precision Medicine Beyond Oncology

Infectious Disease Diagnostics

Multi-Cancer Early Detection

Clinical Biomarkers & Companion Diagnostics